Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease
- Registration Number
- NCT01364688
- Lead Sponsor
- Ramathibodi Hospital
- Brief Summary
Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.
- Detailed Description
Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
- Predialysis chronic kidney disease with GFR < 90 mL/min/1.73m2
- PTH above the upper limit of normal
- serum calcium and phosphate below the upper limit of normal
- changes in GFR>15% during the past 3 months
- receive elemental calcium>500 mg/day
- currently taking active vitamin D, oral calcium with elemental calcium>500 mg/day or bisphosphonate
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment oral alfacalcidol oral alfacalcidol Control no drug No drug
- Primary Outcome Measures
Name Time Method Change in Coronary Artery Calcification 6 months and 12 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
🇹ðŸ‡Phayathai, Bangkok, Thailand